Drug Trial Radar · NCT03158532
Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,040
Actual
Start
Jul 6, 2017
Primary completion
Oct 1, 2021
Study completion Nov 1, 2021
Sponsor
- Lead sponsor
- Instituto de Cardiologia de Santa CatarinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The radial approach for a coronary angiography has became popular in several centers because of its simplicity and fewer complications. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation of future use of the radial artery as an access site for catheterization in the future. Several strategies have been used to decrease the incidence of RAO (heparin, patent hemostasis, etc). Nitrates in intra-arterial have been widely studied in prevention of this spasm. Current data show that nitroglycerin intra-arterial at the end of the procedure reduce the incidence of RAO. The hypothesis that use of nitroglycerin at the start of catheterization would have the same effect was not tested.
Conditions
- Injury of Radial Artery
Interventions
Nitroglycerin IDrug
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo IDrug
Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin IIDrug
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Placebo IIDrug
Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radial Artery OcclusionTime frame: 2 to 24 hours after procedure
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitário Professor Polydoro Ernani de São Thiago
Florianópolis, Santa Catarina, Brazil
Instituto de Cardiologia de Santa Catarina
São Jose, Santa Catarina, Brazil
Irmandade Santa Casa Misericórdia Marília
Marília, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.